Meakins defends his review

Jonathan Meakins, a surgeon at Royal Victoria Hospital in Montreal, followed the presentation of Alpha-Beta Technology Inc.'s Phase I/II study of Betafectin last week with comments that became a focus of controversy surrounding the company's management of the trial.

In an interview with BioCentury on Friday, Meakins responded to complaints that his discussion at the Surgical Infection Society treated the data as if they were from a Phase III trial.